Xenetic Biosciences (XBIO) Stock Price, News & Analysis

Company Overview

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Key Stats

• Today's Range: $2.78 to $2.99
• 50-Day Range: $2.38 to $3.24
• 52-Week Range: $2.20 to $5.20
• Volume: 1,488 shs
• Average Volume: 13,510 shs
• Market Capitalization: $4.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

XBIO Stock Analysis - Frequently Asked Questions

How have XBIO shares performed this year?

Xenetic Biosciences' stock was trading at $3.99 on January 1st, 2025. Since then, XBIO shares have decreased by 27.8% and is now trading at $2.88.
View the best growth stocks for 2025 here.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences, Inc. (NASDAQ:XBIO) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.13. The business earned $0.59 million during the quarter, compared to analysts' expectations of $0.52 million. Xenetic Biosciences had a negative net margin of 142.10% and a negative trailing twelve-month return on equity of 57.31%.

When did Xenetic Biosciences' stock split?

Xenetic Biosciences's stock reverse split before market open on Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Xenetic Biosciences?

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Xenetic Biosciences investors own include FuelCell Energy (FCEL), OPKO Health (OPK), VBI Vaccines (VBIV), Bionano Genomics (BNGO), NIO (NIO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/22/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:XBIO
• CIK: 1534525
• Web: www.xeneticbio.com
• Phone: 781-778-7720
• Fax: N/A
• Employees: 4
• Year Founded: 2011

Profitability

• EPS (Most Recent Fiscal Year): ($2.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.96 million
• Net Margins: -142.10%
• Pretax Margin: -142.06%
• Return on Equity: -57.31%
• Return on Assets: -49.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.20
• Quick Ratio: 8.20

Sales & Book Value

• Annual Sales: $2.50 million
• Price / Sales: 1.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.89 per share
• Price / Book: 0.74

Miscellaneous

• Outstanding Shares: 1,540,000
• Free Float: 1,315,000
• Market Cap: $4.44 million
• Optionable: Not Optionable
• Beta: 2.28